Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113478 · Präparat HOS-093937
7 patients should be monitored (organic cation transporter clinically. High doses of inhibition) trimethoprim/ sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis have not been studied and should be avoided ANTIMYCOBACTERIALS Rifampicin/Abacavir Interaction not studied. Insufficient data to recommend dosage adjustment. Potential to slightly decrease abacavir plasma concentrations through UGT induction. Rifampicin/Lamivudine Interaction not studied. ANTICONVULSANTS Phenobarbital/Abacavir Interaction not studied. Insufficient data to recommend dosage adjustment. Potential to slightly decrease abacavir plasma concentrations through UGT induction. Phenobarbital/Lamivudine Interaction not studied. Phenytoin/Abacavir Interaction not studied. Insufficient data to recommend dosage adjustment. Potential to slightly decrease abacavir plasma concentrations Monitor phenytoin through UGT induction. concentrations. Phenytoin/Lamivudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) phenobarbital (HOS-085617) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 387827645b1a19ba72bcdce583c6ff15cfaff9ba9910317f65a1827bc65c4f3b · Zeichen 3272–5207 im Abschnitt